Trans-Asarone

Trans-Asarone

SCHEMBL940800

CC=Cc1cc(OC)c(OC)cc1OC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HMGCR P04035 1/20 1.00
CYP3A4 P08684 1/20 1.00
NFE2L2 Q16236 2/20 0.59
KDM4E B2RXH2 2/20 0.58
ALDH1A1 P00352 2/20 0.58
TSHR P16473 2/20 0.58
TDP1 Q9NUW8 1/20 0.58
CYP1A1 P04798 5/20 0.57
CYP1B1 Q16678 5/20 0.57
CYP1A2 P05177 4/20 0.57
ABCG2 Q9UNQ0 1/20 0.52
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
NOD2 Q9HC29 2/20 0.43
TYR P14679 1/20 0.42
PRKDC P78527 1/20 0.42
SNCA P37840 1/20 0.42
HPGD P15428 1/20 0.42
HSD17B10 Q99714 1/20 0.42
APP P05067 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trans-Asarone SCHEMBL528746 1.00 HMGCR (1.00) HMGCRCYP3A4NFE2L2KDM4EALDH1A1
Cis-Asarone SCHEMBL29655982 1.00 HMGCR (1.00) HMGCRCYP3A4NFE2L2KDM4EALDH1A1
Cis-Asarone SCHEMBL528747 1.00 HMGCR (1.00) HMGCRCYP3A4NFE2L2KDM4EALDH1A1
Trans-Asarone SCHEMBL29433647 1.00 HMGCR (1.00) HMGCRCYP3A4NFE2L2KDM4EALDH1A1
Trans-Asarone SCHEMBL29268894 0.98 HMGCR (0.95) HMGCRCYP3A4NFE2L2KDM4EALDH1A1
Trans-Asarone SCHEMBL30487992 0.88 CYP3A4 (0.78) HMGCRCYP3A4NFE2L2KDM4EALDH1A1
SCHEMBL13498711 0.85 HMGCR (0.73) HMGCRCYP3A4NFE2L2KDM4EALDH1A1
SCHEMBL13324430 0.85 HMGCR (0.73) HMGCRCYP3A4NFE2L2KDM4EALDH1A1
SCHEMBL12621133 0.85 HMGCR (0.73) HMGCRCYP3A4NFE2L2KDM4EALDH1A1
SCHEMBL3486261 0.83 HMGCR (0.70) HMGCRCYP3A4NFE2L2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1397 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250205310-A1 METHOD FOR REVERSING BODY-WIDE AGE-ASSOCIATED FUNCTIONAL CHANGES THE CHINESE UNIVERSITY OF HONG KONG (CN) 2025-06-26 US claimed
CN-120064478-A UPLC characteristic spectrum of Happy powder, detection method and application thereof 杭州百诚医药科技股份有限公司 2025-05-30 CN claimed
CN-120025234-A Synthesis method of alpha-asarone 湖南威特制药股份有限公司 2025-05-23 CN claimed
CN-119915957-A Thin layer identification method for index components in nerve-soothing and mind-calming pill 安徽中医药大学 2025-05-02 CN claimed
CN-119908505-A Vanillin series electronic atomization liquid, preparation method and electronic atomization device 思摩尔国际控股有限公司 2025-05-02 CN claimed
CN-116554397-B Negative electrode binder of lithium battery and preparation method thereof 深圳市德泰能源有限公司 2025-04-22 CN claimed
CN-119804725-A Construction method of multi-index component HPLC content of traditional Chinese medicine powder reference sample 江苏颐海药业有限责任公司 2025-04-11 CN claimed
CN-119656213-A Skin penetrating paste of mugwort leaf medicine needle and its prepn 山东第二医科大学 2025-03-21 CN claimed
CN-119638715-A Efficient preparation method of tetrahydrofuran type lignan Sumatranin A 西南交通大学 2025-03-18 CN claimed
CN-119310228-B Granule fingerprint spectrum for treating debilitating syndrome and establishing method thereof 中国人民解放军总医院第六医学中心 2025-02-25 CN claimed
CN-1634589-A Injection using invert sugar water solution as carrier YANG XIHONG (CN) 2005-07-06 CN claimed
CN-1615827-A Medicinal powder injection for respiratory system and preparing method LIU WANZHONG (CN) 2005-05-18 CN claimed
EP-1487770-A1 FORMATION OF NEOLIGNAN BY DDQ MEDIATED DIMERISATION OF DIHYDROASARONE Council of Scientific and Industrial Research;an Indian Reg. body incorporated under Reg. of Societies Act (Act XXI of 1860) (IN) 2004-12-22 EP claimed
CN-1511817-A Process for producing alpha-asarone raw material 刘博纯 2004-07-14 CN claimed
WO-2003082786-A1 A PROCESS FOR THE PREPARATION OF PHARMACOLOGICALLY ACTIVE ALPHA-ASARONE FROM TOXIC BETA-ASARONE RICH ACORUS CALAMUS OIL COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2003-10-09 WO claimed
WO-2003080551-A1 FORMATION OF NEOLIGNAN BY DDQ MEDIATED DIMERISATION OF DIHYDROASARONE COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2003-10-02 WO claimed
US-20030113275-A1 Process for the preparation of 1-Propyl-2, 4, 5- trimethoxybenzene from toxic beta-asarone of Acorus calamus or from crude calamus oil containing beta-asarone COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH 2003-06-19 US claimed
CN-1363220-A Method for researching and preparing non-toxic agricultural anthelmintic without environmental pollution WANG LIHUA (CN) 2002-08-14 CN claimed
US-20020035299-A1 Process for the preparation of 1-Propyl-2, 4, 5-trimethoxybenzene from toxic beta-asarone of acorus calamus or from crude calamus oil containing beta-asarone COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH 2002-03-21 US claimed
WO-1996029875-A1 INSECT MONITORING SYSTEMS AND TRAPS EDWARD BILLINGTON & SON LIMITED (GB) 1996-10-03 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020035299-A1 Process for the preparation of 1-Propyl-2, 4, 5-trimethoxybenzene from toxic beta-asarone of acorus calamus or from crude calamus oil containing beta-asarone ADRA2B, CYP1B1, ADRB1 HMGCR 365/4885CYP3A4 47/4885NFE2L2 2027/4885
US-20030113275-A1 Process for the preparation of 1-Propyl-2, 4, 5- trimethoxybenzene from toxic beta-asarone of Acorus calamus or from crude calamus oil containing beta-asarone ADRA2B, CYP1B1, ADRB1 HMGCR 348/4885CYP3A4 46/4885NFE2L2 2015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.